RxEconomics Logo - Health Economics and Outcomes Research Consultancy specializing in AI-driven analytics

Boutique Health Economics and Outcomes Research (HEOR) Consulting

RxEconomics is a boutique HEOR consulting firm that delivers the evidence payers, regulators, and health technology assessment bodies demand—with peer-reviewed rigor, typically 3× faster than traditional consultancies. Founded in 2011 and based in Miami, we serve pharmaceutical, biotech, payer, and policy clients nationally. Every engagement is led directly by Dr. M. Christopher Roebuck, PhD, MBA, a health economist with 28+ years of experience and 120+ publications & research reports. You get senior-level health economics consulting services on every deliverable—not a partner at the pitch and analysts on the project.

Health Economics & Outcomes Research at AI Speed. That is our tagline, and it is also our operating model: we pair rigorous econometrics and biostatistics with an AI-powered HEOR workflow that compresses timelines without compromising quality.

Is This Your Evidence Problem?

Are Payers Asking for Evidence Your Clinical Trial Was Never Designed to Produce?

Trials establish efficacy; payers want real-world value. We build cost-effectiveness analyses, budget impact models, and real-world evidence from healthcare claims data that translate clinical results into the economic terms formulary committees actually use.

Is a Straightforward Economic Model Stuck in a Three-to-Four-Month Queue at Your Current Vendor?

A focused economic model should not take 12-18 weeks. Our AI-enhanced approach typically delivers one in 4-6 weeks—reviewed line by line by a PhD health economist before it reaches you.

Do You Need HTA-Ready Evidence but Lack In-House HEOR Capacity?

Many of our clients have no dedicated HEOR function. We operate as your on-demand health economics and outcomes research consultancy—scoping the evidence plan, executing the analyses, and preparing the value story for payer and HTA audiences.

Is a Policy Change About to Reshape Your Market—and Your Model Assumptions?

Coverage rules, price negotiation, and benefit design shifts can upend an economic case overnight. Our health policy and market access consulting keeps your evidence strategy aligned with where reimbursement policy is heading, not where it was.

Do You Need an Economic Analysis That Will Survive Hostile Scrutiny?

Whether the audience is a national payer, an HTA reviewer, or opposing counsel, our work is built to withstand challenge. The same standards that support our healthcare economic expert witness engagements apply to every model and study we deliver.

Boutique HEOR Consulting vs. the Large CRO Model

Large CROs and global consultancies sell an all-or-nothing proposition: long timelines, layered project teams, and junior staff doing the analysis your name goes on. That model works for sprawling, multi-year programs. It fails when you need a rigorous answer to a specific question—quickly.

RxEconomics is built for the second case:

  • Senior expertise on every task. The economist who scopes your project is the economist who runs the models, checks the code, and presents the results. Nothing is handed down a pyramid.
  • Right-sized engagements. Commission a single budget impact model, a systematic literature review, or a full evidence-generation program. You buy what you need—no bundled minimums.
  • Speed without shortcuts. Our generative AI workflow accelerates claims coding, data preparation, analysis, and research synthesis, and every output is verified by human expertise. The result: exceptional accuracy, typically 3× faster.
  • Direct access. You work with the firm's principal, and you hear back fast—we respond within one business day.

Health Economics Consulting Services

Our HEOR consulting services span the full evidence lifecycle, from early evidence planning through post-launch value demonstration:

  • Cost-effectiveness analysis (CEA) and cost-utility analysis (CUA)
  • Budget impact models (BIM) for payer and formulary submissions
  • Economic burden of illness and cost-of-care studies
  • Global value dossiers (GVD) and AMCP dossier development
  • Systematic literature reviews (SLR) and targeted evidence syntheses
  • Retrospective database studies using commercial, Medicare, and Medicaid claims
  • Comparative effectiveness research
  • Patient-reported outcomes (PRO) analysis and quality-of-life research
  • Medication adherence and treatment pattern analysis
  • Healthcare utilization and cost analyses
  • Plan design and benefit optimization analyses
  • Health technology assessment (HTA) support and payer evidence strategy
  • Value-based contracting analytics
  • Publication strategy, manuscript development, and peer-review support

Need the data engine behind these studies? Our real-world evidence and claims analytics practice works with client-provided, licensed, and public-use data sources including MarketScan, Medicare, Medicaid, and MEPS.

Proof in the Published Record

RxEconomics' published HEOR work includes Medicaid analyses of chronic hepatitis C and direct-acting antiviral treatment—burden-of-illness estimates and a subsequent economic model update. That work used Medicaid data sources including MAX, SDUD, and later TAF/T-MSIS research files to quantify disease burden, treatment uptake, direct medical costs, and the cost offsets associated with curative antiviral therapy.

Dr. Roebuck is also especially known for medication-adherence and medical cost-offset research. His studies in Health Affairs, Medical Care, the Journal of Managed Care & Specialty Pharmacy, and related outlets estimated how increased prescription drug use and improved adherence can reduce hospitalizations, emergency department visits, and nondrug medical spending in chronic disease populations. Those adherence and offset findings have been cited in federal rulemaking analyses, Senate testimony, professional evidence reviews, payer education, and a U.S. patent specification.

Why Clients Choose RxEconomics

28+

Years of Health Economics Experience

120+

Publications & Research Reports

50+

Clients & Institutional Partners Since 2011

3×

Typically Faster Than Traditional Consultancies

1

Business-Day Response Time

Meet Your Health Economist

Dr. M. Christopher Roebuck, PhD, MBA, is President & CEO of RxEconomics and personally leads every engagement. Over a 28+ year career spanning pharmaceutical, payer, and policy sectors—including serving as Director of Strategic Research at CVS Caremark—he has published research in Health Affairs, Medical Care, and the American Economic Review, including widely cited work on medication adherence. His scholarly record is verified through Google Scholar and ORCID, and his analyses have been used by health plans, drug makers, employers, and policymakers.

That publication record is not a trophy case—it is your quality assurance. The methods behind your deliverables are the same ones that have passed peer review at leading journals. Read more about Dr. Roebuck and the firm, or see how we are building an AI-native HEOR research cycle.

Frequently Asked Questions

An HEOR consultancy generates and communicates evidence on the value of healthcare interventions—evaluating costs, outcomes, and quality-of-life impacts so that payers, providers, and policymakers can see which options deliver the best value. In practice, that means designing and executing economic models, cost-effectiveness analyses, budget impact models, real-world evidence studies, and outcomes research, then translating the results into clear value stories for the stakeholders who decide coverage, pricing, and access.

Large CROs typically require full outsourcing to layered project teams, where senior experts sell the work and junior staff perform it. RxEconomics blends advanced AI techniques with rigorous health economics methods, and you receive direct, expert-level guidance from Dr. Roebuck at every step—resulting in clearer answers, faster timelines, and measurable impact. Engagements are right-sized: a single model, a single study, or a complete evidence program.

Common deliverables include cost-effectiveness and cost-utility analyses, budget impact models, global value dossiers, systematic literature reviews, retrospective claims database studies, burden-of-illness analyses, patient-reported outcomes research, and peer-reviewed manuscripts. Every deliverable is built to the methodological standard of the peer-reviewed literature and tailored to its audience—payer, HTA body, journal, or courtroom.

Because AI accelerates the mechanical stages of HEOR work—claims coding, dataset preparation, and literature screening—while a PhD health economist verifies every output, deliverables arrive typically 3× faster than at traditional consultancies. A focused budget impact or cost-effectiveness model generally takes 4-6 weeks rather than the 12-18 weeks common at larger firms, and a full real-world evidence study runs about 3-4 months instead of 9-12 months. Those same efficiencies keep our pricing competitive: you pay for senior expertise, not for layers of project management.

Payers and HTA bodies decide coverage and reimbursement based on demonstrated value—not efficacy alone. HEOR evidence quantifies that value: cost-effectiveness analyses establish value for money, budget impact models show affordability, and real-world studies demonstrate performance in routine care. We identify the evidence most relevant to each decision-maker and package it into value propositions that address their specific priorities, working hand in hand with our health policy and market access practice across the product lifecycle.

Ready to Accelerate Your HEOR Strategy?

Tell us the question you need answered, and we will respond within one business day with a concrete path to the evidence—scope, methods, and timeline. Rigorous health economics, delivered at AI speed.

Request Your Consult